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ABSTRACT 
The mutation spectrum of BRCA1 and BRCA2 presents a wide range of unique mutations in 
breast/ovarian cancer patients but recurrent mutations with founder effects have also been 
described. BRCA2 5344delAATA and 9538delAA are recurrent mutations in Castilla-León (Spain) 
representing 10.6% of BRCA2 positive families. By genotyping eleven chromosome 13 markers 
(4.3 Mb) we demonstrate that each mutation shows core haplotypes of 1.66 Mb and 0.87 Mb, 
respectively, supporting a common ancestor in Castilla-León. Furthermore, both mutations are 
associated with earlier onset of breast cancer (5344delAATA: 37.4 years, p=0.033; 9538delAA: 
39.4 years, p=0.008). The identification of founder effects improves the genetic screening strategy 
to be followed and facilitates the clinical management of asymptomatic carriers 
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INTRODUCTION 
 Germ-line mutations in the breast cancer–susceptibility genes, BRCA1 
(MIM# 113705) [1] and BRCA2 (MIM# 600185) [2], are responsible for 
approximately 16% of the familial risk of breast cancer [3]. BRCA1/2 mutations 
are spread throughout their entire coding regions and splice sites, which makes 
mandatory the complete scanning of both genes. Each population shows a 
particular mutation spectrum in BRCA1 and BRCA2, where specific mutations can 
occur more frequently as a result of founder effects [4,5].The detection of such 
events is a useful tool to establish a routine workflow that could reduce time and 
cost of the screening [5]. In previous works, we reported the mutational spectrum 
of BRCA1 and BRCA2 in breast/ovarian cancer patients from the east of Castilla-
León families where we showed several recurrent BRCA mutations [6-8]. We 
have recently described the presence of founder effects in two mutations, BRCA1 
5272-1G>A and BRCA2 5374delTATG [9]. We also found deleterious BRCA2 
mutations 5344delAATA (c.5116_5119delAATA, premature stop at codon 1710) 
of exon 11 and 9538delAA (c.9310_9311delAA, premature stop at codon 3109) 
of exon 25 in three and five families, respectively, that had not been reported in 
any other populations supporting a putative founder effect in Spain. Mutation 
5344delAATA was described by our group for the first time [6], whereas 
9538delAA had already been reported as the third most prevalent Spanish BRCA2 
mutation (the BIC database, http://research.nhgri.nih.gov/projects/bic/)  [10]. We 
aimed to evaluate the presence of a unique ancestry for each of these mutations in 
order to outline a cost-effectiveness algorithm in Spanish families and to correlate 
clinical characteristics of the disease with each mutation.  
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Patients and Methods 
Selection criteria of breast/ovarian cancer patients of the Inherited Cancer 
Prevention Programme of Castilla y León (788 families-1312 patients and family 
members) were previously published [6]. Mutation detection of BRCA1 and 
BRCA2 was carried out by heteroduplex analysis in capillary array electrophoresis 
[11]. A total of 8 breast/ovarian cancer families harbouring the BRCA2 mutations 
5344delAATA (3 families) and 9538delAA (5 families) were collected for this 
study. Another three 5344delAATA families were recruited from other Spanish 
centres: Hospital de la Santa Creu i Sant Pau (Barcelona), Hospital Universitario 
San Carlos (Madrid) and Hospital La Fe (Valencia) (Table 1). Information about 
the type of cancer in each family, age of diagnosis, age of death or current age and 
geographical origin was also obtained (Table 1). Basic statistical calculations (t-
test) were performed in Excel. 
At least one affected member was genotyped except for family BU-627 
(9538delAA), where all cancer patients died, and family BU-59 (also 9538delAA) 
without any available DNA sample. Therefore, haplotype construction was 
performed in 28 and 32 individuals from six 5344delAATA and four 9538delAA 
families, respectively. Additionally, 75 control individuals were genotyped to 
estimate the allele frequencies of each marker. Previous written informed consent 
was obtained from all participants. 
Ten short tandem repeats (STR) markers (D13S260, D13S1699, 
D13S1698, D13S1697, D13S1701, D13S171, D13S1695, D13S1694, D13S267 
and D13S220) and the SNP 1342C>A of BRCA2 exon 10 were selected to 
construct a haplotype that spans 4.3 Mb of the chromosome 13 region containing 
the BRCA2 gene (Table 1). Primer sequences of microsatellite markers were 
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obtained from the Ensembl database and were amplified by fluorescent-PCR [9]. 
The amplification products were separated on an ABI3130 DNA sequencer and 
analyzed with the GeneMapper v3.7 software (Applied Biosystems, Foster City, 
USA). The SNP 1342C>A (rs144848) was typed by a TaqMan assay in a 7500 
Real Time apparatus (Applied Biosystems) following the manufacturers’ protocol. 
Allele designation was arranged according to a previous report [9]. Subsequently, 
we determined the date of the most recent common ancestor with the equation 
G=log/log(1-), based on the calculation of the linkage disequilibrium between 
the mutation and linked markers [12]. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
6 
Results and Discussion 
BRCA1/2 mutations in Castilla-León (Spain) 
The BRCA1 and BRCA2 genes of 788 unrelated families were scanned for 
mutations. We identified 120 families carrying a deleterious mutation, 44 BRCA1 
(BRCA1+) and 76 BRCA2 positive families (BRCA2+). A total of 55 different 
deleterious mutations were identified, of which 35 were unique and 20 occurred in 
more than one family, including BRCA2 5344delAATA (3 families) and 
9538delAA (5 families) that accounted for 10.6% of BRCA2+ families (Fig. 1). 
Construction of the ancestral haplotype 
The panel of eleven markers between D13S260 to D13S267 was 
genotyped in six independent 5344delAATA families (Table 1). The disease 
associated haplotype could be unambiguously deduced in five families and it was 
present in BU-749 (only index case available). All of them share a conserved 
haplotype along 9 markers (1,660 Kb) that cosegregated with the mutation in all 
the 18 positive carriers, including families M-355 and V-273 from outside of 
Castilla y León, which support the presence of a unique founder effect for this 
mutation. This core haplotype was detected neither in non-carrier family members 
nor in 75 controls. The estimation of mutation age was 76.18 generations (1904 
years, assuming 25 years per generation) with recombinant distal marker 
D13S220, and 8.28 generations ago (207 years) with D13S260. The latter date is 
consistent with the result obtained with Finnish mutations 8555T>G (p.L2776X) 
and 9342-2A>G that share the same chromosomal region between D13S260 and 
D13S267 and were dated 7-11 generations ago [13]. In addition, this BRCA2 
region (nucleotides 5100-6100) seems to be a hotspot for mutations as eight 
different frameshift mutations have been identified in our cohort of patients 
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(22/76 BRCA2+ families: 28.9%). Moreover, only thirty nucleotides downstream 
there is another Spanish founder mutation, 5374delTATG, that is responsible for 
14.5% of our BRCA2+ families [9]. 
With regard to 9538delAA mutation, only four families were available for 
DNA typing (Table 1). All the families showed a conserved haplotype along 870 
Kb, from D13S1697 to D13S1694, also indicating a unique founder effect for this 
mutation. The estimation of the mutation age was 54.6 generations (1,365 years) 
for recombinant marker D13S1698 and 37.37 generations ago (934 years) with 
D13S220. Both dates would have allowed the mutation to spread significantly in 
Spain, which is supported by the fact that 9538delAA is one of the most prevalent 
BRCA2 Spanish mutations and distributed in several regions [10]. In any case, 
calculation of age in both mutations (5344delAATA and 9538delAA) can be 
considered a rough estimate principally due to the small number of families. In 
addition, this value is prone to changes as a result of several factors [14], such as 
differences between the frequencies of founder and recombinant alleles since this 
is the rationale of the estimate. Actually, differences between 5344delAATA and 
9538delAA in estimations with the same recombinant marker (D13S220) are due 
to the different frequencies of the founder allele of both mutations (allele #8 = 
0.45 of 5344delAATA, vs. allele #5= 0.18 of 9538delAA). Despite the plausible 
uneven estimations and given the conservation of the core haplotypes of 
5344delAATA and 9538delAA, we can conclude that each mutation arose from a 
common ancestor in Castilla-León and expanded to other Spanish regions.  
Correlation Genotype-Phenotype 
Among 5344delAATA carriers, seven women had developed breast cancer 
(four of them bilateral) at an average age 37.4 (range 29-55 years old) that is 
significantly lower than the average of BRCA2 mutation carriers (47.5 years; 
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p=0.033) [15]. Therefore, we can conclude that this deletion confers 
predisposition to early onset breast cancer despite this mutation lies in the BRCA2 
ovarian cancer cluster region (OCCR; nucleotides 3035-6629) that has been 
associated with a reduced risk to breast cancer [15,16]. Three out of ten proven 
carrier women (40, 59 and 66 years old) developed ovarian cancer that is very 
similar to the lifetime risk of ovarian cancer in BRCA2 carriers (27%). Mutation 
9538delAA was associated with eleven breast cancer cases, including one breast 
and ovarian cancer and two male breast cancers (family BU-545, Fig. 1b). 
However, no evidence for a correlation between mutation position in BRCA2  and 
risk of male breast cancer have been reported [17]. The medium age for female 
BC was 39.4 years (range 29-60) that is also significantly below the average of 
BRCA2 carriers (p=0.008) [15].  
Concluding Remarks 
We have provided evidence of a unique origin of two BRCA2 mutations, 
which involves an improvement of the cancer genetic counselling in our 
population. Together with previous results, we have reported three BRCA2 
founder mutations that are in part responsible for the disequilibrium towards 
BRCA2+ families (36.7% BRCA1+ vs 63.3% BRCA2+) in our population. 
Another factor that may influence in this result is that, conversely, the most 
prevalent BRCA1 mutation in the rest of Spain (187delAG) [10] has not been 
found in our population until now. In conclusion, each of these mutations likely 
arose from a common ancestor that could be traced to a small area of the region of 
Castilla y León. The constant migratory movements of the Castilla-León 
population during the 20th century may have helped these mutations to spread to 
the rest of Spain. 
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These mutations also contribute to clarify the workflow to launch in 
Spanish families, reducing costs and accelerating the diagnosis in high risk BOC 
families. Based on these results, we can define a panel of four BRCA2 Spanish 
proven founder mutations together with the highly prevalent BRCA2-
3036delACAA (a priori of multiple origin) [18] that would allow to identify 
nearly 50% of BRCA2+ families with only 5 PCR reactions.  Furthermore, in 
these mutations associated with early breast cancer it is essential to detect rapidly 
asymptomatic carriers who may benefit from prevention protocols since survival 
rates of breast cancer are worse than in older women.  
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FIGURE LEGEND 
 
Fig. 1 
Pedigrees of families BU-339 and BU-545 carrying the BRCA2 truncating mutations 
5344delAATA (a) and 9538delAA (b), respectively. Pedigree symbols: black figures, affected 
individuals; half-filled figures, asymptomatic carriers; diagonal slash, deceased individuals; 
arrows, index cases; MBC, male breast cancer. Positive and negative signs after the name of each 
mutation denote carrier or non-carrier status, respectively. The sequencing electropherograms 
corresponding to mutations 5344delAATA (a) and 9538delAA (b) are shown below each pedigree 
  
 
 
 
Family BU-339
Family BU-545
5344delAATA
9538delAA
a
b
BC 48Hepatic 54
5344delAATA+
5344delAATA+
5344delAATA+5344delAATA-
5344delAATA-
BC 38 BC 34
5344delAATA+5344delAATA+
BC 26
5344delAATA-
MBC 76
BC 38
9538delAA+
BC 42
9538delAA+
9538delAA-
9538delAA-
9538delAA-
9538delAA- 9538delAA-
OCMBC 69
9538delAA+
BC 39
9538delAA+9538delAA- 9538delAA-
Unknown Origin
Cancer 45
Figure1
Click here to download Figure: Fig1.ppt
Table 1. Haplotypes associated with 5344delAATA and 9538delAA mutations and clinical characteristics of families.    
 
 
 Haplotypes associated with each mutation 
Marker D13S260 D13S1699 D13S1698 D13S1697 1342C>A D13S1701 D13S171 D13S1695 D13S1694 D13S267 D13S220 
5344delAATA                                         Chromosome 13 position (Mb) 31.33 31.50 31.60 31.76 31.80 32.04 32.15 32.42 32.67 33.16 35.56 
Family  
Index case 
Onset age  
Family History of cancers (Onset age)
b
            
BU-339 34 2 BC (26, 38), Hepatic (54) 4 2 12 3 A 4 8 6 4 6 8 
BU-366 40
OC
 1 BC (44); 2 OC (59, 72), CRC (49) 4 2 12 3 A 4 8 6 4 6 8 
BU-749 
42-59
Bil 
66
OC
 
1 BC (69); Gallbladder (72) 4/4 2/2 12/12 3/3 A/A 4/4 8/8 6/7 4/4 3/6 2/8 
M-355 55 2 BC (44, 46-54
Bil
); CRC (47); Lung (40) 8 2 12 3 A 4 8 6 4 6 2 
SP-135 35-35
Bil
 2 BC (31, 34); 2 OC (47,52); CRC  4 2 12 3 A 4 8 6 4 6 8 
V-273 29-30
Bil
 1 BC (36-42
Bil
); Osteosarcoma  8 2 12 3 A 4 8 6 4 6 2 
  Allele frequencies in Controls (%) 4 (2) 2 (56) 12 (23) 3 (78) A (72) 4 (28) 8 (9) 6 (30) 4 (43) 6 (17) 8 (45) 
9538delAA             
Family  
Index case 
Onset age  
Family History of cancers (Onset age)
b
            
BU-59  51
OC
-52 2 BC (38,other); Larynx  - - - - - - - - - - - 
BU-138 38-40
Bil
 2 BC (34, 55); Pancreas (50); Bladder (66) 9 2 12 3 C 5 8 3 4 9 5 
BU-403  50 2 BC (45, 47) 5 3 10 3 C 5 8 7 
c 
4 9 8 
BU-545  38 2 BC (39, 42); 2 MBC (69, 76)  9 2 12 3 C 5 8 3 4 9 5 
BU-627  0 (70)
a
 6 BC (29-33
Bil
, 31, 32
Bil
, 41, 60, 80-85
Bil
) 9 2 12 3 C 5 8 3 4 9 2 
  Allele frequencies in Controls (%) 9 (18) 2 (56) 12 (23) 3 (78) C (28) 5 (21) 8 (9) 3 (3) 4 (43) 9 (45) 5 (18) 
Types of cancer: BC, breast cancer; OC, ovarian cancer; Bil, bilateral breast cancer; MBC, male breast cancer; CRC; colorectal cancer. Core haplotypes of both mutations are 
shadowed 
a 
Bilateral prophylactic mastectomy performed, the current age is within brackets.  
b 
Carriers or obligate carriers of the familial mutation are underlined.  
c
 Allele 7 of family BU-403 was probably generated by a mutational event since proximal and distal markers maintain the core haplotype 
Table1
Click here to download Table: TABLE_1.doc
